Compare SHIM & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | CELU |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.5M | 56.7M |
| IPO Year | 2023 | N/A |
| Metric | SHIM | CELU |
|---|---|---|
| Price | $2.66 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 38.5K | ★ 64.4K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $495,984,000.00 | $40,578,000.00 |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $6.67 | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.30 | $1.00 |
| 52 Week High | $3.78 | $4.35 |
| Indicator | SHIM | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 60.74 | 55.00 |
| Support Level | $2.47 | $1.62 |
| Resistance Level | $2.78 | $2.18 |
| Average True Range (ATR) | 0.25 | 0.14 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 85.71 | 59.87 |
Shimmick Corp is a provider of water and other critical infrastructure solutions nationwide. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure, including desalination plants. In water resources projects company builds, expands, and improves water storage and conveyance, dams, levees, flood control systems, pump stations, and coastal protection. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains its nation's critical infrastructure, including mass transit, bridges, and military infrastructure.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.